Summary

Market Size & Trends

The U.S. thyroid cancer diagnostics market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 1.48 billion by 2033, growing at a CAGR of around 4.30% from 2025 to 2033. Thyroid cancer diagnostics in the U.S. are rapidly evolving, with 2025 estimates projecting 44,020 new cases and 2,290 deaths. The disease is more common in women, often diagnosed at a younger age, and less prevalent among Black populations. While incidence rose for decades due to overdiagnosis from imaging, stricter criteria have reduced rates by 2% annually since 2014. Advances in genomics, AI-driven imaging, and molecular testing now enable precision medicine, reduce overtreatment, and improve outcomes for aggressive subtypes.

Thyroid cancer diagnostics in the United States are evolving rapidly, shaped by changing incidence trends, risk factors, and advances in molecular tools. In 2025, the American Cancer Society projects about 44,020 new cases (12,670 in men and 31,350 in women) and 2,290 deaths, with diagnosis typically occurring at a younger age (average 51 years). The disease is nearly three times more common in women than in men and is about 40-50% less common among Black populations compared to other groups. Over the past four decades, incidence rose dramatically, largely due to widespread use of sensitive imaging tests that detected small, localized tumors with excellent survival rates-many of which represented overdiagnosis. Since 2014, stricter diagnostic criteria have helped reduce overdiagnosis, leading to a 2% annual decline in incidence, while mortality has remained stable since 2009.

Key etiological insights have emerged alongside these trends. Historically, childhood radiation exposure was the only modifiable risk factor; however, obesity has now been recognized as a major contributor, though its biological mechanisms are not fully understood. Research is also examining the role of endocrine-disrupting chemicals and thyroid dysfunction in disease development. Importantly, genetic and molecular profiling has identified critical mutations-such as BRAFV600E, RAS, RET, and NTRK-that are both prognostic and predictive, offering targets for precision therapies. These discoveries have not only improved disease understanding but have also reshaped diagnostics by integrating molecular assays and next-generation sequencing into biopsy evaluation, allowing better differentiation between benign and malignant nodules.

U.S. Thyroid Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. thyroid cancer diagnostics market report based on cancer, technique, end use, and region:

• Cancer Outlook (Revenue, USD Million, 2021 - 2033)
o Papillary carcinoma
o Follicular carcinoma
o Others
• Technique Outlook (Revenue, USD Million, 2021 - 2033)
o Blood Test
o Imaging
o Biopsy
o Others
• End Use Indication Outlook (Revenue, USD Million, 2021 - 2033)
o Hospital Laboratories
o Cancer Diagnostic Centers
o Research Institutes
o Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Cancer
1.2.2. Technique
1.2.3. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Cancer Outlook
2.2.2. Technique Outlook
2.2.3. End Use Outlook
2.2.4. Regional Outlook
2.3. Competitive Insights
Chapter 3. U.S. Thyroid Cancer Diagnostics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Thyroid Cancer Diagnostics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. U.S. Thyroid Cancer Diagnostics Market: Cancer Business Analysis
4.1. Cancer Segment Dashboard
4.2. Thyroid Cancer Diagnostics Market: Cancer Movement Analysis
4.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Cancer, 2021 to 2033 (USD Million)
4.4. Papillary carcinoma
4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.5. Follicular carcinoma
4.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
4.6. Others
4.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Thyroid Cancer Diagnostics Market: Technique Business Analysis
5.1. Technique Segment Dashboard
5.2. Thyroid Cancer Diagnostics Market: Technique Movement Analysis
5.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By Technique, 2021 to 2033 (USD Million)
5.4. Blood Test
5.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.5. Imaging
5.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.6. Biopsy
5.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
5.7. Others
5.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Thyroid Cancer Diagnostics Market: End Use Business Analysis
6.1. End Use Segment Dashboard
6.2. Thyroid Cancer Diagnostics Market: End Use Movement Analysis
6.3. U.S. Thyroid Cancer Diagnostics Market Size & Trend Analysis, By End Use, 2021 to 2033 (USD Million)
6.4. Hospital Laboratories
6.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
6.5. Cancer Diagnostic Centers
6.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
6.6. Research Institutes
6.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
6.7. Others
6.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key Company Heat Map Analysis, 2024
7.4. Company Profiles
7.4.1. Abbott
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. F.Hoffmann-La Roche Ltd.
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Thermo Fisher Scientific, Inc.
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Siemens Healthcare GmbH
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Bio-Rad Laboratories, Inc.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. GE HealthCare
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Hologic, Inc.
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Koninklijke Philips N.V.
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Toshiba Corporation
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Agilent Technologies, Inc.
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Illumina, Inc.
7.4.11.1. Company Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives